Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 14, 2013

View Archived Issues

Supraspinal antinociceptive activity of the alpha2B-adrenoceptor agonist A-1262543

MiR-155 antagomir ameliorates experimental lupus pulmonary hemorrhage

Phase II study of PsiOxus' MT-102 for cancer-related cachexia meets primary endpoint

Researchers identify novel small-molecule adiponectin receptor agonist for diabetes and obesity

Inhibition of FADK 1-VEGFR-3 interaction investigated at CureFAKtor Pharmaceuticals

Merck Serono and BeiGene sign licensing agreement for BeiGene-290

NM-001: a repurposed drug for CF developed by a small biotech company

UbiVac presents data for its first-in-class lung cancer vaccine

FDA designates MST-188 as an orphan drug for limb ischemia

Anxiolytic and antidyskinetic effects of the novel mGlu5 NAM TR-M-573

Enrollment complete in Baxter's phase III trial of BAX-855

Synergy Pharmaceuticals begins phase III trial of plecanatide

RXi Pharmaceuticals begins phase II study of RXI-109 for hypertrophic scars

Oncodesign and UCB collaborate on new therapeutic agents for neurodegenerative diseases

FDA approves ibrutinib for mantle cell lymphoma

Health Canada approves Opsumit for pulmonary arterial hypertension

Navidea and UCSF collaborate on study of 99mTc-tilmanocept imaging in Kaposi's syndrome

Palatin enters into license option agreement for bremelanotide in Europe

Researchers at Novartis present novel DGAT1 inhibitors

Canadian approval for Eylea in wet AMD

Japanese researchers present new AXL inhibitors for cancer

Hetero Research Foundation divulges new antiviral agents

RaQualia Pharma patents new voltage-gated sodium channel blockers

Trisenox now available in Canada

Theravance synthesizes novel agents for HCV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.